messenger RNA — LLMpedia

messenger RNA
Name	messenger RNA

Contents

messenger RNA is a translatable ribonucleic acid molecule that conveys genetic information from chromosomal DNA to the cellular protein synthesis machinery. It serves as the intermediary between nucleic acid sequences encoded in genomes and polypeptide products synthesized by ribosomes, linking processes studied by investigators such as Frederick Sanger, Max Perutz, Francis Crick, James Watson, and institutions like the Medical Research Council and the Cold Spring Harbor Laboratory. Research into this molecule connects laboratories at the University of Cambridge, Massachusetts Institute of Technology, and biotechnology firms including Moderna, BioNTech, and Pfizer.

Discovery and historical development

The concept of an intermediary between DNA and protein emerged from debates involving scientists at the University of Cambridge, Cold Spring Harbor Laboratory, and the Pasteur Institute during the mid-20th century, influenced by publications from Francis Crick and George Gamow. Early biochemical evidence came from work by Severo Ochoa and Sidney Altman on enzymatic RNA processing at institutions such as the Rockefeller University and the New York University School of Medicine. Experiments in bacterial systems by researchers at the University of Wisconsin–Madison and the Cavendish Laboratory helped establish the transient, heterogeneous nature of the molecule, with subsequent refinement from groups at the National Institutes of Health and the Weizmann Institute of Science defining messenger properties and codon relationships. Later technological advances at companies like Illumina and research centers including the Broad Institute accelerated transcriptome profiling and functional characterization.

The molecule typically comprises a 5' cap structure, a coding sequence flanked by untranslated regions, and a 3' polyadenylated tail, features elucidated by structural biologists at the European Molecular Biology Laboratory and the Max Planck Society. Variants include cytosolic, mitochondrial, and plastid-encoded forms characterized in studies at the Scripps Research Institute, University of California, San Diego, and the University of Tokyo. Alternative splicing generates multiple isoforms discovered through collaborations between the Wellcome Trust Sanger Institute and the Genome Institute at Washington University, while specialized classes—such as long noncoding-associated transcripts and short unstable species—were profiled by teams at the Dana-Farber Cancer Institute and the Fred Hutchinson Cancer Research Center.

Transcription by RNA polymerases, initiation factors, and chromatin remodelers characterized at the National Center for Biotechnology Information and the Max Planck Institute for Molecular Genetics produces primary transcripts that undergo capping, splicing, cleavage, and polyadenylation, processes detailed in work from the Rockefeller University and the University of Oxford. The spliceosome machinery, revealed by structural studies at the MRC Laboratory of Molecular Biology and the European Synchrotron Radiation Facility, removes introns and assembles exons, while cap-binding proteins identified by labs at the Pasteur Institute and the University of California, Berkeley promote nuclear export through interactions with nuclear pore complexes studied at the ETH Zurich. RNA-binding proteins and helicases characterized at the Fred Hutchinson Cancer Research Center regulate processing kinetics and alternative isoform selection.

As an information carrier, the molecule specifies amino acid sequences decoded by the genetic code articulated by groups at the Salk Institute for Biological Studies and the University of Cambridge. It integrates regulatory inputs from transcription factors mapped by consortia such as the ENCODE Project and mediates responses to signaling pathways investigated at the Harvard Medical School and the Yale School of Medicine. Differential isoform expression underlies developmental programs examined by teams at the Karolinska Institutet and the Johns Hopkins University School of Medicine, while dysregulation contributes to pathologies researched at the Mayo Clinic and the Memorial Sloan Kettering Cancer Center.

Ribosome recruitment, initiation factor dynamics, and codon usage biases were dissected by groups at the Wadsworth Center, University of California, San Francisco, and the Institute of Molecular Biology (Singapore). Translation elongation and termination involve factors characterized at the Centre national de la recherche scientifique and the Institute of Cancer Research, and are modulated by microRNAs first described by investigators at the Cold Spring Harbor Laboratory and the University of Kansas Medical Center. Stress-responsive regulation through upstream open reading frames and internal ribosome entry sites was elucidated in studies at the University of Pennsylvania and the St. Jude Children's Research Hospital.

mRNA surveillance pathways—nonsense-mediated decay, nonstop decay, and no-go decay—were defined by laboratories at the European Molecular Biology Laboratory and the Fred Hutchinson Cancer Research Center, with exonuclease complexes such as the exosome and decapping enzymes characterized by teams at the Max Planck Institute for Biochemistry and the Institute for Protein Research (Osaka). Quality control intersects with ubiquitin-proteasome systems investigated at the Weizmann Institute of Science and the University of Toronto and with stress granule dynamics described by researchers at the University of Edinburgh and the University of Basel.

Synthetic and modified transcripts underpin vaccines and therapeutics developed by companies like Moderna and BioNTech, with regulatory oversight from agencies including the Food and Drug Administration and the European Medicines Agency. Delivery platforms—lipid nanoparticles, viral vectors, and polymeric systems—were advanced by teams at the University of Pennsylvania, the Massachusetts General Hospital, and commercial entities such as CureVac. Transcript engineering enables protein replacement, immunotherapy, and gene editing applications pursued at the Broad Institute, Roche, and the National Institutes of Health. Clinical trials coordinated by centers like the Mayo Clinic and consortia such as the NIH Clinical Center continue to expand indications and safety profiles.

Category:Ribonucleic acids